EUCTR2015-002886-53-Outside-EU/EEA进行中（未招募）不适用
A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf® (tacrolimus)/MMF, and Extended Release (XL) Tacrolimus /MMF in de novo Kidney Transplant Recipients
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patient is a recipient of a primary or retransplanted cadaveric or non-HLA-identical living kidney transplant.
- •- Patient is age greater or equal to 12 years.
- •- Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to enrollment or upon hospitalization.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 5
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1. Patient has previously received or is receiving an organ transplant other than a kidney.
- •2. Patient has received a kidney transplant from a non-heart beating donor.
- •3. Patient has received an ABO incompatible donor kidney.
- •4. Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV).
- •5. Patient has a current malignancy or a history of malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully.
- •6. Patient has significant liver disease, defined as having during the past 28 days continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 3 times the upper value of the normal range of the investigational site.
- •7. Patient has an uncontrolled concomitant infection or any other unstable medical condition that could interfere with the study objectives.
- •8. Patient is currently taking or has been taking an investigational drug in the 30 days prior to transplant.
- •9. Patient is receiving everolimus or enteric coated mycophenolic acid at any time during the study.
- •10. Patient has a known hypersensitivity to tacrolimus, mycophenolate mofetil or corticosteroids.
- •11. Patient is pregnant or lactating.
- •12. Patient is unlikely to comply with the visits scheduled in the protocol.
- •13. Patient has any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication with the investigator.
研究者
相似试验
进行中（未招募）
不适用
Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes MellitusEUCTR2009-011221-13-Outside-EU/EEATakeda Global Research & Development Center, Inc.48
已完成
1 期
A multicenter, open label, comparative study to evaluate and compare Safety, Tolerability And Immunogenicity Of 10-Valent Pneumococcal Polysaccharide Conjugate Vaccine in healthy infantCTRI/2014/04/004543Panacea Biotec Limited72
进行中（未招募）
1 期
A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who areExperiencing Insufficient Efficacy with Risperidone and/or Safety and Tolerability Issues,While on Risperidone.SchizophreniaEUCTR2005-000472-40-ESBristol-Myers Squibb International Corporation450
进行中（未招募）
不适用
A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who areExperiencing Insufficient Efficacy with Risperidone and/or Safety and Tolerability Issues,While on Risperidone. Version 1.0 .SchizophreniaEUCTR2005-000472-40-ATBristol-Myers Squibb International Corporation430
进行中（未招募）
不适用
A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who areExperiencing Insufficient Efficacy with Risperidone and/or Safety and Tolerability Issues,While on Risperidone. Version 1.0 + Amendment 1.SchizophreniaEUCTR2005-000472-40-HUBristol-Myers Squibb International Corporation450